Brazil · Delayed Price · Currency is BRL Hospital Mater Dei Earnings Call Transcripts
Fiscal Year 2026
-
Record Q1 2026 results with net revenue up 15% and EBITDA up 35% year-over-year, driven by higher average ticket, operational efficiency, and strong performance in oncology. Leverage improved, margins expanded, and disciplined capital allocation remains a priority.
Fiscal Year 2025
-
Record revenue and EBITDA were achieved through higher average ticket, operational efficiency, and growth in oncology and surgical complexity. Strong cash generation enabled deleveraging, while key units like Salvador and Nova Lima outperformed, supporting a positive outlook.
-
Record Q2 2025 revenue and EBITDA were achieved through higher complexity procedures, operational efficiency, and disciplined cost control. Key units like Salvador and Nova Lima delivered strong growth, while leverage and cash flow improved, supporting further debt prepayment and expansion plans.
-
Record net revenue and margin improvements were achieved, driven by operational efficiency, strong performance in Salvador and Nova Lima, and growth in non-bed revenues. Cash flow enabled share buybacks and an extraordinary dividend, while Fitch reaffirmed the positive rating.
Fiscal Year 2024
-
2024 saw revenue and occupancy growth despite sector challenges, with cost pressures from regulatory changes and a focus on operational efficiency. New hospital ramp-ups and partnerships are set to drive margin recovery and cash generation in 2025.
-
A new hospital opening has driven positive operational results, while cost pressures from the Nursing Bill and NDI issues remain a challenge. Ongoing policy improvements and negotiations aim to enhance efficiency and financial performance.
-
Revenue grew 8% year-over-year for the first half, but Q2 margins were pressured by the nursing bill, higher NPLs, and seasonality. July and August showed strong recovery in occupancy and mix, with new units ramping up and supply chain projects expected to offset cost pressures.